74. Prolactin secreting pituitary adenoma Clinical trials / Disease details
Clinical trials : 18 / Drugs : 33 - (DrugBank : 10) / Drug target genes : 16 - Drug target pathways : 65
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03717454 (ClinicalTrials.gov) | December 1, 2018 | 14/10/2018 | Dopamine D2 Receptors(D2R) Imaging in Prolactinomas | The Predictive Value of Positron Emission Tomography-Magnetic Resonance (PET-MR) Mediated Dopamine D2 Receptors Imaging in the Drug Therapy of of Prolactinomas. | Prolactinoma | Other: Surgery;Drug: Drug treatment | Zhebao Wu | Xinqiao Hospital of Chongqing;First Hospital of China Medical University;Beijing Tiantan Hospital;First Affiliated Hospital of Wenzhou Medical University;First Affiliated Hospital of Fujian Medical University;Peking Union Medical College Hospital;Huashan Hospital;Chinese PLA General Hospital | Not yet recruiting | 18 Years | 65 Years | All | 50 | N/A | NULL |